Product Description
A hormone made from testosterone in the prostate, testes, and certain other tissues. It is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. High amounts of androstanolone may increase the growth of prostate cancer and make it harder to treat. Also called DHT and dihydrotestosterone. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/androstanolone)
Mechanisms of Action: AR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Transdermal,Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: France | India | Slovenia | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Ascend
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Bone Cancer|Prostate Cancer|Protein Deficiency|Bladder Cancer|Inflammation|Hypogonadism|Testicular Cancer|Pituitary Cancer|Pregnancy Outcomes|Hypopituitarism|Prostatic Diseases|Skin Diseases, Vascular|Vascular Cancer|Prostatic Hyperplasia|Hypothalamic Diseases|Hypothalamic Cancer|Testicular Diseases|Deficiency Diseases|Anal Gland Cancer|Skin Cancer|Breast Cancer|Pituitary Diseases
Phase 1: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FDHT - version 1, 9 March 2015 | P2 |
Terminated |
Prostate Cancer |
2018-09-15 |
|
| [18F]FDHT PET in hormone naive prostate cancer | P2 |
Active, not recruiting |
Bone Cancer|Prostate Cancer |
2016-02-11 |
|
| 2012-003981-42 | P2 |
Completed |
Breast Cancer |
2015-05-13 |
|
| IRB00015971 | P1 |
Terminated |
Prostate Cancer |
2013-03-01 |